WW domain-containing oxidoreductase (WWOX), a putative tumour suppressor, is suggested to be involved in the hyperphosphorylation of Alzheimer's Tau. Tau is a microtubule-associated protein that has an important role in microtubule assembly and stability. Glycogen synthase kinase 3b (GSK3b) has a vital role in Tau hyperphosphorylation at its microtubulebinding domains. Hyperphosphorylated Tau has a low affinity for microtubules, thus disrupting microtubule stability. Bioinformatics analysis indicated that WWOX contains two potential GSK3b-binding FXXXLI/VXRLE motifs. Immunofluorescence, immunoprecipitation and molecular modelling showed that WWOX interacts physically with GSK3b. We demonstrated biochemically that WWOX can bind directly to GSK3b through its short-chain alcohol dehydrogenase/reductase domain. Moreover, the overexpression of WWOX inhibited GSK3b-stimulated S396 and S404 phosphorylation within the microtubule domains of Tau, indicating that WWOX is involved in regulating GSK3b activity in cells. WWOX repressed GSK3b activity, restored the microtubule assembly activity of Tau and promoted neurite outgrowth in SH-SY5Y cells. Conversely, RNAi-mediated knockdown of WWOX in retinoic acid (RA)-differentiated SH-SY5Y cells inhibited neurite outgrowth. These results suggest that WWOX is likely to be involved in regulating GSK3b activity, reducing the level of phosphorylated Tau, and subsequently promoting neurite outgrowth during neuron differentiation. In summary, our data reveal a novel mechanism by which WWOX promotes neuronal differentiation in response to RA. is a 46 kDa protein that has been implicated in human tumourigenesis, nervous system development and Alzheimer's disease (AD).
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is a 46 kDa protein that has been implicated in human tumourigenesis, nervous system development and Alzheimer's disease (AD). [2] [3] [4] WWOX contains two N-terminal WW domains (containing conserved tryptophan residues) and one COOHterminal short-chain alcohol dehydrogenase/reductase (ADH/ SDR) domain. Both the WW and ADH domains mediate protein-protein interactions. The WWOX has been reported to bind to many proteins, including p53, p73, erythroblastic leukaemia viral oncogene homolog 4, ezrin, activator protein-2 g, small integral membrane protein of the lysosome/late endosome, c-Jun N-terminal kinase 1 and mouse double mutant 2. 5, 6 Although some studies have suggested that WWOX might have a critical role in regulating Tau hyperphosphorylation, 2 the details of this regulation remain unclear. Glycogen synthase kinase 3b (GSK3b), a serine/threonine kinase that was first identified based on its ability to phosphorylate glycogen synthase and regulate glycogen metabolism, is now known to be a key kinase in several important signalling pathways. The dysregulation of GSK3b is involved in several major human diseases, including diabetes, cancer, AD and bipolar disorder. 7 Researchers have reported a number of proteins that associate with GSK3b and regulate its activity. The strongest examples is Axin, which are involved in the Wnt signalling pathway. 2, 8 Chou et al. 9 used the yeast twohybrid method to identify a novel GSK3b interacting protein, GSKIP, which can bind to GSK3b and inhibit its kinase activity.
The role of GSK3b in regulating neural cell differentiation is controversial. GSK3b has been shown to facilitate neurite outgrowth by preventing E2F1 from inhibiting the transcription of the cell cycle inhibitors p21 and p15. 10 However, other evidence has indicated that the inactivation of GSK3b results in collapsin response mediator protein 2 (CRMP-2) dephosphorylation, which leads to enhanced microtubule polymerisation and axon growth. 11 Therefore, the function of GSK3b in the regulation of neural differentiation remains unclear.
Chen et al. 12 reported that WWOX likely has a role in the development of the nervous system. They found that WWOX was differentially expressed during various stages of brain development in mice, indicating a potential role for WWOX in promoting neuronal differentiation and maturation. 12 However, the molecular mechanism by which WWOX facilitates neural differentiation has yet to be revealed. In this study, we demonstrated that WWOX enhances retinoic acid (RA)-mediated neurite outgrowth and identified a novel mechanism through which WWOX promotes neurite outgrowth by interacting with and suppressing GSK3b kinase activity in the presence of RA. Our findings suggest that the regulation of GSK3b activity by WWOX has a vital role in RA-induced neural-cell differentiation.
Results
WWOX is required for neuronal cell differentiation. RA can induce neuroblastomal differentiation in SH-SY5Y cells. [13] [14] [15] From 1 to 4 days after RA induction, SH-SY5Y cells progressively underwent phenotypic changes that were compatible with neuron-like morphology, characterised by neurite outgrowth (Figure 1a ). The expression of the neuronal marker bIII-tubulin progressively increased over 4 days of RA treatment (Figure 1b) . The expression of cyclin D1, a cell-cycle progression marker, gradually decreased during the RA treatment. Increased expression of WWOX Figure 2b were quantified by scanning the autoradiogram using a densitometer. (d) SH-SY5Y cells were transfected with two pre-designed siRNA targeting WWOX for 24 h, and the resulting cell lysates were subjected to western blot analysis. (e) SH-SY5Y cells were transfected with either control siRNA or WWOX siRNA as indicated. After 24 h of transfection, cells were washed, and the medium was replaced with 1% serum including 10 mM RA. Cells with neurites longer than twice the length of the cell body were counted. Data are presented as the mean ± S.E. from three independent experiments. *Po0.05, **Po0.01 when compared with the mock control was observed in the RA-treated SH-SY5Y cells, accompanying the decreased phosphorylation of Tau at both S396 and S404; phosphorylation at S422 was unchanged (Figures 1b and c) . Since studies have shown that S404 and S396 may be phosphorylated by GSK3b in vivo, 16 we also examined whether the phosphorylation level of GSK3b and its downstream target, b-catenin, are affected by RA treatment. We found that the phosphorylation levels of phospho-GSK3b S9 and phospho-b-catenin remained normal. We therefore suspected that the reduced GSK3b-mediated Tau phosphorylation and increased WWOX expression are indispensable for RA-induced SH-SY5Y cell differentiation. Furthermore, SH-SY5Y cells in which WWOX expression was reduced by RNAi showed increased pTau S396 levels and notably decreased neurite outgrowth (Figures 1d and e) . Collectively, these results indicate that WWOX may have a vital role in SH-SY5Y cell differentiation and in Tau phosphorylation.
WWOX interacts and colocalises with GSK3b in vivo.
Herná ndez et al. 16 demonstrated that S396 and S404 on Tau are GSK3b-dependent phosphorylation sites. Thus, we presumed that WWOX-dependent dephosphorylation of Tau occurred through an inhibition of GSK3b activity. We performed a bioinformatic analysis to align WWOX with well-known GSK3b inhibitors (Figure 2a ) and found that WWOX 296À320 and WWOX 388À412 contain FXXXLI/ VXRLE, a highly conserved GSK3b-binding motif within GSKIP 115À139 , Axin 381À405 , and FRAT 205À229. Previous reports have shown that GID 381À405 , a 25-amino acid region of Axin, is critical for its association with GSK3b. 8 Interestingly, WWOX 296À320 and WWOX 388À412 are similar to GID 381À405 in Axin (Figure 2a ). WWOX 296À320 is 40% similar to Axin1 381À405 , 32% similar to Axin2 363À387 , 36% similar to FRAT1 205À229 and 34% similar to GSKIP 115À139 . WWOX 388À412 is 26% similar to Axin1 381À405 , 34% similar to Axin2 363À387 , 36% similar to FRAT1 205À229 and 32% Figure 2 WWOX physically interacts and colocalises with GSK3b in vitro and in vivo. (a) Upper panel: the amino acid sequence of WWOX 296À320 , which is similar to highly conserved regions of Axin1 381À405 , Axin2 363À387 , FRAT1 205À229 and GSKIP 115À139 , is highlighted in grey. Lower panel: the amino acid sequence of WWOX 388À412 , which is similar to highly conserved regions of Axin1 381À405 , Axin2 363À387 , FRAT1 205À229 and GSKIP 115À139 , is highlighted in grey. Identical amino acids are highlighted in black. (b) SH-SY5Y cells were co-transfected with pEGFP-GSK3b and pcDNA3.1-HA-WWOX constructs for 24 h. Cells were fixed with 3.7% formaldehyde, permeabilised, and incubated with mouse anti-HA primary antibodies and rhodamine-conjugated secondary antibodies. The cells were then observed using a Zeiss LSM510 confocal microscope. (c) Cells were harvested for immunoprecipitation using anti-WWOX (left) or anti-GSK3b (right) antibodies. WWOX-associated GSK3b was recognised by antiGSK3b. Anti-HA was used to detect overexpressed HA-tagged WWOX. (d) SH-SY5Y cells were transiently transfected with the WWOX-HA construct and treated with RA for 24 h. The cells were harvested for immunoprecipitation with anti-GSK3b. Immunoprecipitated GSK3b was recognised by antibodies against GSK3b. Anti-HA was used to detect HA-tagged WWOX. (e) Mouse brain extract was subjected to immunoprecipitation using anti-WWOX or anti-GSK3b as indicated. The immunoprecipitated complex was separated by molecular weight using SDS-PAGE. Anti-WWOX or anti-GSK3b antibodies were used to detect WWOX or GSK3b on the PVDF membrane similar to GSKIP 115À139 (Figure 2a) . These results suggested that WWOX may interact with GSK3b. Hence, we performed immunofluorescence and immunoprecipitation experiments to determine whether WWOX is associated with GSK3b. First, SH-SY5Y cells were co-transfected with plasmids expressing GSK3b fused to green fluorescent protein (GFP) (GFP-GSK3b) and WWOX-HA to examine the in vivo association of WWOX and GSK3b. Confocal fluorescent microscopy demonstrated that WWOX and GSK3b colocalised in the cytoplasm of SH-SY5Y cells (Figure 2b) . We then performed co-immunoprecipitation experiments to confirm the in vivo interaction between WWOX and GSK3b in SH-SY5Y cells. Cell extracts were prepared from SH-SY5Y cells that had been transiently transfected with the WWOX-HA construct. Figure 2c (left panel) shows that the anti-HA antibodies precipitated HA-tagged WWOX, and that endogenous GSK3b coprecipitated with the WWOX protein complex. Similarly, ectopic HA-tagged WWOX was co-immunoprecipitated by anti-GSK3b antibodies (Figure 2c , right panel).
We considered the possibility that WWOX could regulate Tau phosphorylation through direct interaction. In Supplementary Figure A , however, we show that although WWOX-HA can be immunoprecipitated with anti-HA antibodies, Tau was not co-immunoprecipitated in the complex (Supplementary Figure A) , indicating that WWOX does not stably interact with Tau in SH-SY5Y cells. To clarify whether the interaction between WWOX and GSK3b is affected by RA treatment, we performed co-immunoprecipitation experiments in cells that had been stimulated with RA. SH-SY5Y cells were transiently transfected with the WWOX construct to mimic the upregulation of WWOX by RA treatment. Figure 2d shows that the amount of GSK3b co-immunoprecipitated by WWOX from RA-treated SH-SY5Y cells was similar to the amount precipitated in untreated controls. Subsequently, immunoprecipitation was performed in mouse brain extracts to verify the physiological interaction between WWOX and GSK3b. Figure 2e shows that both GSK3b and WWOX were precipitated by anti-GSK3b or anti-WWOX antibodies. These results indicate that WWOX physiologically associates and colocalises with GSK3b in vivo.
The WWOX-GSK3B interaction is mediated by a conserved motif in WWOX. To narrow down the binding site on WWOX that is responsible for its binding to GSK3b, various WWOX functional domains, ww1 (1-60 a.a.), ww2 (40-110 a.a.), ww (1-110 a.a.) and ADH (110-414 a.a.), were expressed as glutathione S-transferase (GST) fusions in E. coli and affinity-purified on glutathione beads ( Figure 3a ). As shown in Figure 3b , the result of GST pulldown assay reveals an intense anti-GSK3b band was bound by the full-length WWOX and ADH-domain affinity matrix ( Figure 3b , lanes 6 and 7), but not by GST alone (lane 2) or the other WWOX domains (lanes 3-5) examined. These results suggest that GSK3b interacts with WWOX by binding to its ADH domain.
Additionally, the GST pull-down assay demonstrated that neither WWOX-D389 (1-389 a.a.) nor WWOX-D286 (1-286 a.a.) were able to interact with GSK3b ( Figure 3c ). This indicates that WWOX amino acids 388-407 are required for its interaction with GSK3b. Furthermore, bioinformatics analyses revealed that L404 was highly conserved in WWOX and other GSK3b-binding proteins (Figure 2a ). In order to clarify whether L404 within the highly conserved GSK3b-binding motif, LXXRL, has an important role in GSK3b binding, a GST pull-down assay was performed using two WWOX mutants, L404A and L311A. As shown in Figure 3d , the mutation of L404A, but not L311A, completely abolishes the binding of WWOX to GSK3b. These results suggest that WWOX physically interacts with GSK3b in vitro through the L404-containing motif within the WWOX 388À407 region. Finally, the co-immunoprecipitation experiment was performed again to compare wild-type (WT) WWOX with these mutants. As expected, ectopic GFP-WWOX can be co-immunoprecipitated by endogenous GSK3b, and this interaction was diminished when L404 mutated to alanine ( Figure 3e , right panel). Similar results were found in a co-immunoprecipitation experiment using GFP antibodies against GFP-tagged WWOX proteins ( Figure 3e , left panel).
To investigate the possibility that the L404 mutant is incorrectly folded, thus disrupting GSK3b-WWOX interaction, we conducted co-immunoprecipitation experiments using c-jun, a WWOX-binding protein. C-jun was immunoprecipitated by either WT or mutant WWOX-GFP, indicating that WWOX L404A is folded correctly. 17 To understand how WWOX associates with GSK3b, we simulated the interaction in silico using molecular modelling. Figure 3f illustrates the interaction between GSK3b and WWOX 388À407 . The overview in Figure 3f shows that the motif portion of WWOX 388À407 (highlighted in light pink and dark pink, respectively), especially L400, R403 and L404, are in close contact with a binding pocket a-helix (G262-L273, red) and loop (N285-H299, green) on GSK3b. Figures 3g and h and Supplementary Figure B show close-up views of WWOX 388À407 interacting with the binding pocket a-helix and loop, respectively. As indicated in Figure 3g , the interactions between WWOX 388À407 and the binding pocket a-helix are hydrophobic (indicated by red dashed lines) and electrostatic (indicated by green dashed lines). The van der Waals interactions included WWOX 388À407 L400 with a number of consecutive hydrophobic residues, including V263, L266, V267 and I270; WWOX 388À407 L404 with V267 and L270; and WWOX 388À407 A399 with V263. A similar helix-helix ridge-groove hydrophobic interaction was also present in the GSK3b-GSKIPtide 18 and GSK3b-AxinGID 19 structures. Similarly, the contact between WWOX 388À407 and the GSK3b-binding loop was a simple hydrophobic interaction between L400 and F293, and between L404 and I296. Collectively, these results revealed that the L404-containing motif located within WWOX 388À407 is essential for the association of WWOX and GSK3b.
GSK3b kinase activity is negatively regulated by WWOX. We next investigated the functional effect of WWOX in regulating GSK3b activity. We performed an in vitro kinase assay to examine whether WWOX interferes with GSK3b-mediated Tau phosphorylation. GST-tagged WWOX protein (0.3 mg) and His-GSK3b protein (30 ng) were incubated in reaction buffer for 30 min before adding 0.5 mg His-Tau protein and a [g-32 P] ATP cocktail.
The GSK3b-mediated Tau phosphorylation was examined by autoradiography and western blotting analysis. As shown in Figure 4a , GSK3b can phosphorylate Tau in vitro, and this phosphorylation is completely abolished in the presence of excess WWOX, but not GST or WWOX L404A. Moreover, we demonstrated that GSK3b-mediated Tau phosphorylation at S396 and S404 was reduced in a dose-dependent manner by GST-WWOX (Figure 4b ). In the same experiment, we investigated the specificity of the effect of WWOX on GSK3b-mediated Tau phosphorylation by examining the phosphorylation of S422, which is phosphorylated by MKK4 kinase in vivo (Figure 4c ). SH-SY5Y cells were transiently transfected with GFP and GFP-WWOX for 12 h, and the cell lysate was subjected to western blotting. Ectopically expressed WWOX significantly inhibited Tau phosphorylation at S404 and S396 but not S422. However, this inhibition was diminished when WWOX L404A was used. These results again confirm our finding that the binding of WWOX to GSK3b is required for its inhibition of GSK3b-mediated Tau phosphorylation. The phosphorylation of Tau S422 is not affected by WWOX (Figure 4c) , suggesting that the inhibition of GSK3b through the binding of WWOX is highly specific, at least in SH-SY5Y cells. Moreover, we examined the effect of WWOX on the activity of GSK3b toward the peptide substrate GS-1, which is derived from glycogen synthase. Consistent with our observations of Tau phosphorylation, WT but not mutant WWOX inhibits GSK3b phosphorylation of GS-1 (Supplementary Figure C) . We subsequently performed a competitive inhibition assay to further support our conclusion using WWOXtide 388À407 , a WWOX-derived peptide, in the in vitro kinase assay experiment. WWOXtide 388À407, but not the control scrambled peptide, inhibited GSK3b activity and reduced Tau phosphorylation, as shown by autoradiography (Figure 4d) . Collectively, The reaction was stopped by adding 2 Â sample buffer and heating at 100 1C for 10 min. This was followed by SDS-PAGE, and phosphorylation signals were evaluated using autoradiography. (b) WWOX (1, 3 and 10 mg) inhibited Tau phosphorylation by GSK3b in a dose-dependent manner. GST-WWOX was pre-incubated with His-GSK3b for 30 min in a reaction buffer including optimised quantities of ATP and Tau protein. The reactions were then subjected to western blot analysis of Tau, pTauS396 and S404. (c) SH-SY5Y cells were transiently transfected with GFP, GFP-WWOX or GFP-WWOX L404A. Cells were lysed, and a western blot analysis was carried out using antibodies against pTauS396, pTauS404, pTauS422, Tau and actin. Actin expression was evaluated to verify equal loading, and GFP expression was evaluated to confirm the protein expression level. (d) A scrambled peptide and WWOXtide 388À407 were each incubated with 30 ng His-GSK3b, ATP-cocktail, and 10 Ci of [g-32 P] ATP for 10 min at 20 1C. The reaction was stopped by adding 2 Â sample buffer and was followed by SDS-PAGE. Phosphorylation was detected with autoradiography our results reveal that WWOX negatively regulates GSK3b kinase activity on the neuron-specific microtubule-binding protein Tau in SH-SY5Y cells.
WWOX promotes neuronal cell differentiation through the inhibition of GSK3b. Researchers have suggested that GSK3b has an important role in cell differentiation. We therefore investigated whether GSK3b inactivation is involved in RA-stimulated neuronal cell differentiation. SH-SY5Y cells were transiently transfected with a GFP control or GSK3b (WT, S9A or kinase dead (KD), or R96A) for 24 h, and the neurite outgrowth of SH-SY5Y cells, indicating neuronal cell differentiation, was analysed. Transfection with GFP-GSK3b WT and S9A notably decreased SH-SY5Y cell differentiation, whereas KD and R96A did not affect SH-SY5Y cell differentiation compared with the GFP control (Figures 5a and b) . GSK3b small interference RNA (siRNA) was used to knock down GSK3b protein expression to confirm the crucial role of GSK3b inactivation in RA-mediated axon growth. SH-SY5Y cells were transfected with GSK3b siRNA, followed by treatment with 10 mM RA for 1 to 4 days. Compared with the control scrambled-RNAi group, the GSK3b protein-knockdown group showed significantly increased neurite outgrowth percentage beginning on the second day of RA treatment (Figures 5c and d) . Thus, our results showed that GSK3b could negatively regulate neurite outgrowth in RA-stimulated neuronal cells.
Microtubule polymerisation is indispensable in neurons because neurite growth is severely disrupted when polymerisation is inhibited, indicating that a constant flux of microtubules is required for axonal growth. Furthermore, evidence shows that the phosphorylation of Tau by GSK3b affects the ability of Tau to promote microtubule formation. [20] [21] [22] This evidence, in addition to the results of this study, suggests that WWOX may promote neuronal cell differentiation by inhibiting GSK3b-mediated Tau phosphorylation. We therefore used a light-scattering assay to clarify how WWOX and GSK3b affect Tau-mediated microtubule assembly. As shown in Figure 5e , we measured the effect of GSK3b on the turbidimetric time course of microtubule assembly. GSK3b diminished the microtubule assembly, as reflected by decreased turbidity. However, the new equilibrium reached a higher turbidity when treated with WT WWOX and GSK3b than with GSK3b alone. Interestingly, the GSK3b-binding deficient WWOX, WWOX L404A, could not restore the microtubule assembly activity. In conclusion, our data demonstrated that WWOX could restore the ability of Tau to promote microtubule formation by inhibiting GSK3b activity.
WWOX L404A, which is deficient in binding to GSK3b ( Figure 3 ) and was incapable of restoring Tau activity on microtubule formation (Figure 5e ), should fail to stimulate neuronal cell differentiation. To confirm this prediction, the SH-SY5Y cell differentiation promoted by WWOX L404A was examined and compared with that of WT WWOX. WT WWOX and WWOX L404A were separately overexpressed in SH-SY5Y in the presence of RA treatment. WWOX significantly increased the percentage of differentiated SH-SY5Y cells. However, this increase was abolished when L404 was mutated to alanine. These results strongly suggest that WWOX promotes neuronal differentiation in SH-SY5Y cells by inhibiting the GSK3b-mediated phosphorylation of the microtubule-binding protein Tau (Figures 5f and g ).
To demonstrate that Tau is indeed the ultimate effector of WWOX/GSK3b-dependent neuronal cell differentiation, we performed double manipulation of WWOX and GSK3b, as well as the delivering of siRNA to knock down Tau and GSK3b, respectively, and then conducted RA-induced neurite outgrowth experiments. Figures 6a and b (lanes 1-3) show that the neurite outgrowth stimulated by RA was abolished when Tau was knocked down. Western blotting (Figure 6b) confirmed protein overexpression or knockdown after transient transfection of the WWOX-expressing vector or Tau and GSK3b siRNAs. Neuronal differentiation increased to 44% in the WWOX overexpression group comparing with 18% of RAcontrol cells group (lane 6). This increase was completely abolished when Tau was knocked down in a double manipulation experiment (lane 5). Similar results were exhibited in a GSK3b and Tau double manipulation experiment, which showed that neuronal cell differentiation of the GSK3b knockdown group increased approximately 25% more than the RA-control (lane 7), which was completely abolished when Tau was knocked down (lane 4). Neither WWOX overexpression nor GSK3b knockdown promoted neurite outgrowth in the Tau knockdown condition, indicating that Tau is the effector of both WWOX and GSK3b (Figures 6a and b) . Interestingly, co-transfection of the WWOX plasmid and GSK3b siRNA followed by RA treatment did not show an additive or synergistic effect compared with WWOX overexpression alone or GSK3b knockdown alone (Figures 6a  and b, lane 8) . WWOX did not further promote neurite outgrowth in the presence of GSK3b siRNA, consistent with the hypothesis that WWOX promotes neuronal differentiation through GSK3b inhibition. Collectively, these results connect WWOX, GSK3b and Tau in an exclusive, direct manner and show that WWOX promotes neuronal SH-SY5Y cell differentiation through inhibiting the GSK3b-mediated phosphorylation of the microtubule-binding protein, Tau.
Discussion
In this study, we found two GSK3b consensus-binding sites in the WWOX amino-acid sequence. Furthermore, our results show that WWOX physically interacts with GSK3b only through the WWOX 388À407 region, which is an L404-containing motif. Some reports suggest that L400 is also important for WWOX to associate with GSK3b. Smalley et al. 19 demonstrated that L392 and L396 are essential for the interaction between Axin1 and GSK3b. Interestingly, the L392 and L396 of Axin1 are related to L400 and L404, respectively. These results show that WWOX interacts with GSK3b through a structure and sequence similar to that of Axin 381À405 . Furthermore, researchers have suggested that GSK3b has an important role in multiple cellular processes, including protein synthesis, glycogen metabolism, proliferation, microtubule dynamics and cell differentiation. 23 WWOX may help to control certain types of cellular processes through the inhibition of GSK3b.
WWOX expression in the developing brain is low during the early embryonic stage when organogenesis is most rapid; however, moderate-to-high WWOX immunoreactivity is detected in the brain and spinal cord during the middle and late fetal stages. 12 This strongly suggests that WWOX may have an important role in neuron differentiation. In this study, highly differentiated SH-SY5Y cells were correlated with high WWOX protein expression and low Tau S396 and S404 protein phosphorylation. This indicates that SH-SY5Y cell differentiation requires WWOX protein expression and lower pTau S396 and pTau S404 levels, possibly caused by the inhibition of GSK3b. Intriguingly, Sze's group demonstrated that the downregulation of WWOX induces Figure 5 WWOX regulates neuronal differentiation through its interaction with GSK3b. (a) SH-SY5Y cells were transfected with GFP, GFP-GSK3b WT, S9A, K8586MI and R96A for 24 h. The cells were then treated with 10 mM RA for 24 h. Cells with neurites longer than twice the length of the cell body were counted. Data are presented as the mean±S.E. from three independent experiments. **Po0.01 compared with the GFP control. (b) Western blot analysis confirmed the expression of the GFP-fusion protein by the anti-GFP antibody. (c) SH-SY5Y cells were transfected with pre-designed siRNA targeting GSK3b for 24 h and treated with 10 mM RA for 1 to 4 days. Cells with neurites longer than twice the length of the cell body were counted. Bright-field results are shown to indicate post-differentiation status at 24 h. Data are presented as the mean ± S.E. from three independent experiments. *Po0.05 compared with mock control. (d) Cells were treated with siRNA and lysed in 2 Â sample buffer. Western blot analysis was carried out using antibodies against GSK3b. The blot was stained for actin to verify equal loading. (e) Tau protein was incubated with GST, GST-WWOX or GST-WWOX L404A in the presence of GSK3b for the microtubule assembly assay. The reaction mixture also contained tubulin protein, GTP, and reaction buffer. The reaction mixture was incubated at 37 1C in a thermostatic spectrophotometer, and the change in reflectance over time was measured at 350 nm. (f) SH-SY5Y cells were transfected with empty vector, GFP-WWOX or GFP-WWOXL404A, as indicated. After transfection, cells were washed, and the medium was replaced with 1% serum and treated with 10 mM RA. The photos were taken on day 1. (g) The percentage of differentiated cells with neurites longer than twice the length of the cell body was calculated. The data are presented as the mean ± S.E. from three independent experiments. *Po0.05 compared with the mock-treated control Tau phosphorylation. They also showed that WWOX was downregulated in AD patients. 2 Furthermore, the level of active GSK3b is reportedly increased in AD. 24 Based on our results, we speculate that the upregulation of GSK3b, and therefore Tau phosphorylation, in AD may due to the downregulation of WWOX.
Chen et al. 12 reported that WWOX was differentially expressed during various stages of brain development in mice, indicating its potential role in promoting neuronal differentiation and maturation. They also used a yeast two-hybrid assay to demonstrate that WWOX associates with Tau and showed that the downregulation of WWOX may induce Tau phosphorylation in vitro.
2 However, the molecular mechanism by which WWOX facilitates neural differentiation has yet to be revealed. Here, we were not able to detect a Tau-WWOX complex in our co-immunoprecipitation experiment from SH-SY5Y cells (Supplementary Figure A) ; the inconsistency in results may due to the different expression systems used. However, our results connect WWOX, GSK3b and Tau in an exclusive, direct manner and describe a novel The extension of immature neurites requires the assembly of a stable microtubule infrastructure. Microtubule polymerisation and stability are regulated by a number of microtubuleassociated proteins, including Tau. GSK3b regulates Tau through phosphorylation; hyperphosphorylated Tau has a decreased affinity for microtubules and disrupts microtubule stability. This study shows that the knockdown of GSK3b expression through RNAi decreases Tau phosphorylation and increases the occurrence of SH-SY5Y cell differentiation. Additionally, researchers have reported that the inactivation of GSK3b results in the dephosphorylation of the GSK3b downstream target, CRMP-2, which leads to enhanced microtubule polymerisation and axon growth. 11 Therefore, neurite outgrowth requires microtubule assembly and the inhibition of GSK3b activity. However, a number of previous studies have reported that the activation of GSK3b enhanced neurite growth rates in PC12, NT2 or SH-SY5Y cells. [25] [26] [27] However, our microtubule assembly assay clearly showed that WWOX restores the microtubule assembly-promoting activity of Tau that is repressed by GSK3b. Ahmad et al. 21 reported that the inhibition of microtubule polymerisation compromises axonal growth. We observed highly phosphorylated Tau in undifferentiated SH-SY5Y cells. Reduced Tau phosphorylation also correlated strongly with WWOX expression in highly differentiated SH-SY5Y cells. These results provide evidence that WWOX has an important role in inhibiting GSK3b activity and suppressing Tau hyperphosphorylation.
In conclusion, our study demonstrates that WWOX physically interacts with GSK3b through its ADH/SDR domain and decreases Tau protein hyperphosphorylation at S404 and S396, both in vivo and in vitro. Furthermore, we showed that an increased WWOX protein level is correlated with decreased pTau S396 and S404 levels in highly differentiated SH-SY5Y cells. The microtubule assembly will eventually be promoted by Tau when GSK3b is inhibited by WWOX during RA-stimulated neuronal cell differentiation. We thus present a novel mechanism for the regulation of neuronal differentiation by WWOX.
Materials and Methods
Cell culture, transfection and treatments. Human neuroblastoma SH-SY5Y cells were maintained in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum and antibiotics (100 mg/ml streptomycin and 100 IU/ml penicillin; Life Technologies, Inc., Gaithersburg, MD, USA). The cells were grown to subconfluence and then treated with 10 mM RA for 1 to 5 days. The information of siRNA used in this study was provided in Supplementary Table 1 . For efficient transfection, Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used according to the manufacturer's instructions.
Plasmid construction. A full-length WWOX (human WOX1) construct was subcloned into the following expression vectors: pEGFP-C1-CPO, pGEX-KG and pcDNA3.1-HA-CPO. The ADH domain fragment was generated by PCR with pfu polymerase (Promega, Madison, WI, USA). The PCR product was subcloned into the pGEX-KG, pEGFP-C1-CPO and pcDNA3.1-HA-CPO plasmids for sequence verification and further cloning.
WWOX mutants (L311A and L404A) were prepared using site-directed mutagenesis and a two-step PCR technique. After successful cloning, the WWOX cDNA insert sequences were further confirmed through DNA sequencing.
Western blotting. Cells were disrupted in 2X sample buffer (0.1 M Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 2% b-mercaptoethanol), boiled for 10 min, centrifuged, placed on ice for several minutes, stored at À80 1C and then separated using 10-12.5% SDS-polyacrylamide gel electrophoresis (PAGE). Proteins were then electrotransferred onto PVDF transfer membranes (Millipore, Lincoln Park, NJ, USA). The membranes were blocked with 5% nonfat milk in TBST buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Tween 20) containing 5% bovine serum albumin at 4 1C for 2 h or overnight, and incubated for 2 h at room temperature with one of the following primary antibodies: monoclonal anti-GFP (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-GSK3b (BD Transduction Laboratories, Lexington, KY, USA), monoclonal anti-actin (Sigma, St. Louis, MO, USA), Tau (Millipore), rabbit anti-pTau S396 (Origene, Rockville, MD, USA), rabbit anti-pTau S404 (Millipore) or rabbit anti-pTauS422 (Abcam, London, UK). The membranes were washed with TBST six times every 10 min. Immunoreactive proteins were detected using horseradish peroxidase-conjugated secondary antibodies and then the membrane was washed with TBST six times every 10 min during the detection process. The protein signal was detected by an enhanced chemiluminescence system (ECL Plus; Perkin Elmer Life and Analytical Sciences, Inc., Waltham, MA, USA).
Immunoprecipitation
and GST pull-down assays. For immunoprecipitation, SH-SY5Y cells were washed twice with phosphate-buffered saline (PBS) at the indicated times and lysed in ice-cold RIPA buffer (100 mM HEPES pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.5% Tween 20, 0.1% Triton X-100, 1 mM DTT, 50 mg/ml AEBSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 5 mM NaF and 1 mM Na 3 VO 4 ). Anti-WWOX antibodies were incubated with Protein G-Sepharose beads for 1 h at 4 1C, and the pretreated cell lysates were added to the Protein G-Sepharose beads for 2 h at 4 1C. The immune complexes were then washed three times with a RIPA buffer, eluted by boiling in a 2X SDS sample buffer, and subjected to western blotting analysis. For GST pull-down assays, GST or GST-WWOX proteins expressed in BL21 (DE3) were adsorbed to glutathione-agarose beads (Sigma) for 1 h after three washes with PBS. The beads were then washed three times with the same buffer. Sample buffer was added, and the beads were boiled and subjected to western blot analysis.
Immunofluorescence assays. SH-SY5Y cells co-transfected with pcDNA3.1-HA-WWOX and GFP-GSK3b were grown on coverslips, washed in PBS, fixed with 3.7% paraformaldehyde in PBS, and permeabilised by incubation in 10% Triton X-100. Following permeabilisation, the cells were washed with PBS and incubated with a mouse anti-HA monoclonal antibody (Santa Cruz Biotechnology) at 4 1C overnight. The cells were washed again and then incubated with goat anti-mouse IgG rhodamine (Santa Cruz Biotechnology). The cells were washed again and subsequently stained with DAPI. In each instance, the cells were washed in PBS. Fluorescently labelled protein localisation was visualised using a Zeiss laser confocal microscope (LSM510; Zeiss Inc, Oberkochen, Germany).
In vitro kinase assay. His-tagged human Tau and His-tagged human GSK3b were expressed in E. coli BL21 and purified by means of affinity chromatography. The purity of the recombinant proteins was verified by SDS-PAGE. The purified recombinant GSK3b protein was pre-incubated with WT or mutant GST-WWOX and 25 mg/ml His-Tau for 30 min, and the kinase reaction was initiated by the addition of an equal volume of 2X reaction buffer (100 mM HEPES, pH 7.4, 1 mM DTT and 10% glycerol) and ATP cocktail (20 mM ATP and 1 mM MgCl 2 ). After incubating the mixtures at 30 1C for up to 20 min, the reaction was stopped by adding 2 Â sample buffer and heating at 100 1C for 10 min. The proteins were further separated using SDS-PAGE. Results were detected using autoradiography or western blotting.
Molecular dynamics simulation. A molecular dynamics (MDs) simulation was employed to predict the binding interaction between GSK3b and WWOX 388À407 . As the structure of WWOX is unknown, the GOR IV Secondary Structure Prediction Method 28 was used to predict the structure of the WWOX 388À407 peptide. Accordingly, the structure of the GSK3b-AxinGID complex (PDB entry code: 1O9U) was used as a template to create an initial structure for the GSK3b-WWOX 388À407 complex. The structure of AxinGID was extracted from the complex, and the amino acids were modified to generate WWOX 388À407 . The resulting WWOX 388À407 peptide was then subjected to energy minimisation in which the backbone was constrained and the side chains were allowed to achieve their proper orientations using 5000 steps of the steepest descent algorithm and 5000 steps of the conjugate gradient algorithm. The X-ray
